Fig. 1. In vivo fates of patient-derived AML cells defined by mutational profile. In vivo fates of patient-derived AML cells defined by mutational profile.

Slides:

Advertisements

Similar presentations

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

Advertisements

Hepatic differentiation and transplantation of induced pluripotent stem cells 2015/08/23.

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,

The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice by Peter J. Turnbaugh, Vanessa K. Ridaura, Jeremiah.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Transfer of miR-223 during neutrophil-epithelial cell interactions

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 4 Bacterial taxonomic groups that discriminate among RYGB-, SHAM-, and WMS-derived samples. Bacterial taxonomic groups that discriminate among RYGB-,

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 1. Anemia in patients with central diabetes insipidus.

Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.

Fig. 1 Increasing UCB cell dose impairs short-term progenitor cell engraftment. Increasing UCB cell dose impairs short-term progenitor cell engraftment.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 3. Frequencies of amino acids at critical PGT121 and contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.

Fig. 6. Pathway analysis of CMLD

Fig. 8. In vivo suppression of MM by CMLD

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA

Fig. 2. GPC3 expression in normal and tumor tissues.

Increased ADMA in pregnancy is associated with SGA birth outcomes

Fig. 5. Vascularization of human liver seed grafts.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 5. In vivo characterization of adipogenesis by CT.

Fig. 4. MATE1 transcription in RCC.

Fig. 2 STED microscopy of isolated cardiomyocytes from mice treated with MP-rhodamine–loaded CaPs. STED microscopy of isolated cardiomyocytes from mice.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.

Fig. 6. Apoptotic MSCs exert in vivo immunosuppression in a TH2-type inflammation model in the absence of cytotoxic cells. Apoptotic MSCs exert in vivo.

Fig. 4. BLU-285 demonstrates antitumor activity across multiple KIT-driven in vivo disease models. BLU-285 demonstrates antitumor activity across multiple.

Persistence of CAR4 cells is reduced after sustained TCR engagement

Fig. 4. Restriction of TCR antigen to hematopoietic tissues does not prevent CAR8 exhaustion and failure of leukemia clearance. Restriction of TCR antigen.

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

Fig. 7 Human study design for device testing.

Fig. 3. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation.

Role of immune and inflammatory cells in lung cancer–associated PH

Fig. 3. The effects of DCA on hemodynamic and functional end points and their association with genetic factors (variants of the SIRT3 and UCP2 genes) that.

Fig. 1. Map showing the study catchment area in the East of England.

Fig. 7. ApoMSCs exert immunosuppressive activity in GvHD and elicit IDO in engulfing recipient phagocytes. ApoMSCs exert immunosuppressive activity in.

Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 4. Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue. Irisin protected against oxidative stress and apoptosis in IR-injured.

Fig. 7 CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα. CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα.

Fig. 7. Genetic ablation of UCP2 compromised the protective effect of exogenous irisin on lung IR injury. Genetic ablation of UCP2 compromised the protective.

Fig. 1 HSCT: A platform for cellular therapies.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Human HFpEF is associated with impaired cardiac myofibril relaxation

Fig. 3 FMAEs promote infection by VSVΔ51.

CD facilitates RCT in vivo and promotes urinary cholesterol excretion

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Fig. 5. Induction of apoptosis via enhanced BCL-2 dependence in FLT3-ITD+ AML cells with diverse coexisting somatic mutations by in vivo kinase inhibition.

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 1 Differentiation of human peripheral blood monocytes into MDMi cells induces a microglial gene expression and functional phenotype. Differentiation.

Fig. 2 Activation of freshly isolated CD4+ T cells from HIV-infected patients on ART results in successive increases in elongated, polyadenylated, and.

Fig. 7 Vaccine-induced influenza-specific B cells are not maintained in peripheral blood. Vaccine-induced influenza-specific B cells are not maintained.

Fig. 5 ALRN-6924 shows robust antileukemic activity in primary AML cells and in vivo. ALRN-6924 shows robust antileukemic activity in primary AML cells.

Fig. 5 HDAC inhibition blocks age-dependent diastolic dysfunction.

Fig. 6. Eradication of FLT3-ITD+ AML cells in vivo through combined inhibition of kinase and antiapoptotic pathways. Eradication of FLT3-ITD+ AML cells.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 1 Neutrophils derived from patients with MPNs are associated with an increase in NET formation and a prothrombotic, NET-rich phenotype. Neutrophils.

Fig. 4 ALRN-6924 inhibits cellular proliferation and clonogenic capacity, and induces cell cycle arrest and apoptosis in AML cell lines. ALRN-6924 inhibits.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Developmental potential of BMSSCs clones in vivo.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Presentation transcript:

Fig. 1. In vivo fates of patient-derived AML cells defined by mutational profile. In vivo fates of patient-derived AML cells defined by mutational profile. (A) Somatic mutation profiles were identified in patient cell subpopulations defined by surface phenotype based on developmental hierarchy of human hematopoiesis. (B) The in vivo fate of each subpopulation was determined through transplantation into newborn NSG mice. If repopulation by multilineage hematopoiesis occurred, then the transplanted subpopulation contained hematopoietic or preleukemic stem cells; if AML engraftment occurred, then the transplanted subpopulation contained LICs. Yoriko Saito et al., Sci Transl Med 2017;9:eaao1214 Published by AAAS